<DOC>
	<DOCNO>NCT02451098</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-blind , Active-controlled , Parallel group , Factorial Design , Phase III Clinical Trial .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety CKD-391</brief_title>
	<detailed_description>The aim phase 3 study evaluate efficacy safety CKD-391 daily 8 week patient primary hypercholesterolemia . Furthermore , extension study additional 12 week design confirm long term safety CKD-391 .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Adult , least 19 year age . Hyperlipidemia patient LDLC≤250 mg/dl TG ≤400 mg/dl Patients require antidyslipidemia drug therapy [ base NCEP ATP III ( 2002 ) ] Drug compliance Runin period ≥70 % Patients must willing study sign informed consent Patients myopathy include rhabdomyolysis CPK level≥2xULN Patients acute arterial disease Patients renal dysfunction Serum creatinine level ≥2x ULN Patients liver dysfunction ALT , AST level &gt; 2xULN Patients medical history within 6 month prior screen visit ( Heart failure , uncontrolled arrhythmia , drug alcohol abuse history , gastrointestinal disease surgery , anticoagulation disease ) Patient uncontrolled disease ( diabetes mellitus HbA1c level &gt; 9.0 % , hypertension SBP≥180mmHg DBP≥110mmHg , hypothyroidism TSH≥1.5xULN ) Patients history presence active malignancy within 5 year Patients difficulty stop take lipidlowering agent runin period . Patients take another investigational drug within 4 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>